The abstract is read at the publisher; the summary is JClub's.
A dedicated inpatient Parkinson’s disease program reduced contraindicated-medication dosing and multiple levodopa error metrics in 366 monitored admissions from January–June 2024.
- Why it matters: Hospitalized people with Parkinson’s disease are at elevated risk for medication errors and discharge to non-home settings, both linked to adverse outcomes.
- What they did: In 2023, the team implemented an inpatient program using EHR census identification, movement-disorders-trained advanced practitioner regimen alignment, customized EHR alerts and levodopa orders, pharmacist support, and staff education. Medication error rates and discharge outcomes were compared with a pre-implementation retrospective cohort from 2018.
- The result: From pre-implementation to January–June 2024, median contraindicated doses fell from 2 (IQR 1–6) to 1 (IQR 1–2) (p=0.015), levodopa deviation days decreased from 43.1% to 38.3% (p<0.0001), and non-home discharge dropped from 44.8% to 38.3% (p=0.038).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.